TY  - JOUR
AU  - Hermann, Peter
AU  - Villar-Piqué, Anna
AU  - Schmitz, Matthias
AU  - Schmidt, Christian
AU  - Varges, Daniela
AU  - Goebel, Stefan
AU  - Bunck, Timothy
AU  - Lindemann, Hanna
AU  - Bogner, Carla
AU  - Santana, Isabel
AU  - Baldeiras, Inês
AU  - Riggert, Joachim
AU  - Zerr, Inga
AU  - Llorens Torres, Francesc Josep
TI  - Plasma Lipocalin 2 in Alzheimer's disease: potential utility in the differential diagnosis and relationship with other biomarkers.
JO  - Alzheimer's research & therapy
VL  - 14
IS  - 1
SN  - 1758-9193
CY  - London
PB  - BioMed Central
M1  - DZNE-2022-00194
SP  - 9
PY  - 2022
AB  - Lipocalin-2 is a glycoprotein that is involved in various physiological and pathophysiological processes. In the brain, it is expressed in response to vascular and other brain injury, as well as in Alzheimer's disease in reactive microglia and astrocytes. Plasma Lipocalin-2 has been proposed as a biomarker for Alzheimer's disease but available data is scarce and inconsistent. Thus, we evaluated plasma Lipocalin-2 in the context of Alzheimer's disease, differential diagnoses, other biomarkers, and clinical data.For this two-center case-control study, we analyzed Lipocalin-2 concentrations in plasma samples from a cohort of n = 407 individuals. The diagnostic groups comprised Alzheimer's disease (n = 74), vascular dementia (n = 28), other important differential diagnoses (n = 221), and healthy controls (n = 84). Main results were validated in an independent cohort with patients with Alzheimer's disease (n = 19), mild cognitive impairment (n = 27), and healthy individuals (n = 28).Plasma Lipocalin-2 was significantly lower in Alzheimer's disease compared to healthy controls (p < 0.001) and all other groups (p < 0.01) except for mixed dementia (vascular and Alzheimer's pathologic changes). Areas under the curve from receiver operation characteristics for the discrimination of Alzheimer's disease and healthy controls were 0.783 (95
KW  - Alzheimer Disease: blood
KW  - Alzheimer Disease: cerebrospinal fluid
KW  - Alzheimer Disease: diagnosis
KW  - Amyloid beta-Peptides: blood
KW  - Amyloid beta-Peptides: cerebrospinal fluid
KW  - Biomarkers: blood
KW  - Biomarkers: cerebrospinal fluid
KW  - Case-Control Studies
KW  - Cognitive Dysfunction: diagnosis
KW  - Diagnosis, Differential
KW  - Humans
KW  - Lipocalin-2: blood
KW  - tau Proteins
KW  - Alzheimer’s disease (Other)
KW  - Biomarker (Other)
KW  - Dementia (Other)
KW  - Lipocalin 2 (Other)
KW  - Neutrophil gelatinase-associated Lipocalin (Other)
KW  - Plasma (Other)
KW  - Amyloid beta-Peptides (NLM Chemicals)
KW  - Biomarkers (NLM Chemicals)
KW  - Lipocalin-2 (NLM Chemicals)
KW  - tau Proteins (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:35027079
C2  - pmc:PMC8759265
DO  - DOI:10.1186/s13195-021-00955-9
UR  - https://pub.dzne.de/record/163434
ER  -